MIRA (MIRA Pharmaceuticals, Inc.) Stock Market Reviews

crown

search

Read and share opinions on MIRA (MIRA Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

MIRA

MIRA Pharmaceuticals, Inc.

clarify Drug Manufacturers - General

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Specialist Direct's ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes
Oct 30, 2025
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Oct 24, 2025
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
Oct 16, 2025
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Sep 30, 2025
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
Sep 16, 2025
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
Sep 12, 2025
Mira Introduces Ultra4™, the First At-Home Hormone Monitor with Lab-Quality 4-in-1 Testing
Aug 25, 2025
MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
Aug 19, 2025
MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
Jul 29, 2025
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
Jul 3, 2025
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Jun 30, 2025
EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
Jun 30, 2025
MIRA Data Shows Improved Weight Loss Potential
Jun 30, 2025

Reviews